Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 4 (2007), Issue 8 (August)

1. Trastuzumab use for metastatic breast cancer in pregnancy.
   Obstet Gynecol, 110(2): 507-10. [Abstract] [Full-text]
2. Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study.
   Anticancer Drugs, 18(8): 963-8. [Abstract] [Full-text]
3. Biodegradable nanoparticles for targeted ultrasound imaging of breast cancer cells in vitro.
   Phys Med Biol, 52(16): 4739-47. [Abstract] [Full-text]
4. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
   J Nucl Med, 48(8): 1357-68. [Abstract] [Full-text]
5. Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors.
   Oncologist, 12(7): 766-73. [Abstract] [Full-text]
6. A review of the use of trastuzumab (Herceptin(R)) plus vinorelbine in metastatic breast cancer.
   Ann Oncol, 18(7): 1152-8. [Abstract] [Full-text]
7. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
   Ann Oncol, 18(7): 1133-44. [Abstract] [Full-text]
8. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
   J Clin Oncol, 25(23): 3525-33. [Abstract] [Full-text]
9. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
   Breast Cancer Res, 9(4): R50. [Abstract] [Full-text]
10. Comparative economic analysis of aromatase inhibitors and tamoxifen in the treatment of hormone-dependent breast cancer.
    Expert Opin Pharmacother, 8(11): 1675-91. [Abstract] [Full-text]
11. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
    Cancer Sci, 98(9): 1498-503. [Abstract] [Full-text]
12. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity.
    Ann Oncol, 18(8): 1335-41. [Abstract] [Full-text]
13. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma.
    Br J Cancer, 97(4): 494-501. [Abstract] [Full-text]
14. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
    Clin Cancer Res, 13(16): 4909-19. [Abstract] [Full-text]
15. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
    Hum Pathol, 38(9): 1386-93. [Abstract] [Full-text]
16. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    J Clin Oncol, 25(24): 3712-8. [Abstract] [Full-text]
17. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia--monitoring the effect of an expensive medicine access program.
    J Clin Oncol, 25(24): 3688-93. [Abstract] [Full-text]
18. Recent advances in the treatment of salivary gland cancers: Emphasis on molecular targeted therapy.
    Oral Oncol, 43(8): 729-34. [Abstract] [Full-text]
19. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure.
    Circulation, 116(8): 954-60. [Abstract] [Full-text]
20. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
    Oncogene, 26(39): 5793-807. [Abstract] [Full-text]
21. Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer.
    Expert Opin Pharmacother, 8(13): 2189-204. [Abstract] [Full-text]
22. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.
    BMC Cancer, 7: 153. [Abstract] [Full-text]
23. Origins of breast cancer subtypes and therapeutic implications.
    Nat Clin Pract Oncol, 4(9): 516-25. [Abstract] [Full-text]
24. Mechanisms of disease: angiogenesis and the management of breast cancer.
    Nat Clin Pract Oncol, 4(9): 536-50. [Abstract] [Full-text]
25. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
    J Clin Oncol, 25(25): 3991-4008. [Abstract] [Full-text]
26. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
    J Clin Oncol, 25(25): 3853-8. [Abstract] [Full-text]
27. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
    J Clin Oncol, 25(25): 3808-15. [Abstract] [Full-text]
28. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
    J Clin Oncol, 25(25): 3859-65. [Abstract] [Full-text]
29. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial.
    Ann Oncol, 18(9): 1493-9. [Abstract] [Full-text]
30. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer.
    Ann Oncol, 18(9): 1484-92. [Abstract] [Full-text]

© 2004-2010 Herceptin Research Today. All Rights Reserved.